SEC Form 4 · accession 0001824720-26-000004
MYRIAD GENETICS INC · MYGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rashmi Kumar
Director
Period of report
Jun 8, 2026
Accepted (ET)
Jun 9, 2026 · 4:20 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000899923
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 8, 2026 | S | 15,000 | $4.4562 | D | 171,889 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.37 to $4.63, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.